. 2017 Jul 28;216(6):651–661. doi: 10.1093/infdis/jix367

Table 2.

Odds Ratios for Mortality in Human Immunodeficiency Virus–Infected Infants by 6-Month Biomarker Levels

Biomarker	<25th Percentile (Ref)	25–49th Percentile	50th–74th Percentile	≥75th Percentile
Biomarker	OR	OR (95% CI)	OR (95% CI)	OR (95% CI)
I-FABP (23 cases/108 controls)^a
Unadjusted	1.0	3.2 (.9–11.4)	2.0 (.5–7.4)	0.5 (.1–2.8)
Adjusted^b	1.0	4.0 (.6–28.7)	2.5 (.3–22.6)	0.5 (.0–6.4)
sCD14 (23 cases/119 controls)^a
Unadjusted	1.0	3.7 (.9–14.9)	0.7 (.1–4.3)	3.8 (.9–15.5)
Adjusted^b	1.0	1.2 (.2–8.9)	0.5 (.0–7.0)	2.3 (.4–14.6)
IL-6 (13 cases/60 controls)^a
Unadjusted	1.0	0.5 (.0–6.0)	1.7 (.2–11.6)	5.4 (.9–31.0)
Adjusted^b	1.0	NA^c	4.1 (.2–80.8)	2.1 (.1–43.1)
CRP (20 cases/108 controls)^a
Unadjusted	1.0	1.0 (.2–4.4)	2.0 (.5–7.5)	1.3 (.3–5.3)
Adjusted^b	1.0	0.3 (.0–5.6)	1.6 (.2–12.5)	1.7 (.2–12.4)

Abbreviations: CI, confidence interval; CRP, C-reactive protein; I-FABP, intestinal fatty acid binding protein; IL-6, interleukin 6; NA, not applicable; OR, odds ratio; sCD14, soluble CD14.

^aThe number of cases and controls with available data is shown for each biomarker.

^bOdds ratio for mortality between 6 and 12 months of age based on quartiles of biomarkers measured in plasma at 6 months of age, adjusted for maternal parity and marital status, and infant sex, 6-month weight, and 6-week viral load in a logistic regression model.

^cCould not be estimated due to insufficient data.